Merck & Co., Inc.
MRKNew York Stock ExchangeFull coverage
Latest dossier
AI-generated
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers
Q3 of fiscal year 2026 · Published Nov 1, 2026,
Merck & Co. sells prescription medicines, vaccines and animal-health products, and its cancer drug KEYTRUDA made about half of 2025 sales before its main US patent ends in 2028 and Medicare price setting begins in 2029. In the third quarter of 2026 sales rose 4.7%, but most of that came from the timing of purchases, while new products, including the injectable KEYTRUDA QLEX, rose to 13.6% of sales from 5.1% a year earlier. Merck spent about $26.4 billion on three acquisitions to build the replacement, and its reported earnings this year are cut by large deal charges. Moatsight estimates revenue of about $68.7 billion over the next four quarters, with the outcome resting on how fast the new products grow and what Merck pays for the next ones.
What you pay
| Figure | At the close | 5-yr median | 5-yr range |
|---|---|---|---|
| P/E | No value: no close yet | No value: no price history | |
| EV/Sales | No value: no close yet | No value: no price history | |
| EV/EBITDA | No value: no close yet | No value: no price history | |
| Price/FCF | No value: no close yet | No value: no price history | |
| Market cap | No value: no close yet | ||
| Net debt and other claims(enterprise value minus market cap) | No value: no close yet | ||
| Enterprise value | No value: no close yet |
How the business is doing
| Figure | Last 12 months | 1-year change1-year | Yearly, 3 years | 8 quarters |
|---|---|---|---|---|
| Revenue | $67.4B | +4.9%(better for the company) | +4.3% | Each quarter is listed in the row's details. |
| Diluted EPS | $0.99 | −87.0%(worse for the company) | −18.2% | Each quarter is listed in the row's details. |
| Free cash flow | $14.7B | +13.0%(better for the company) | +3.8% | Each quarter is listed in the row's details. |
| Gross margin | 71.8% | −5.4 pp(worse for the company) | −0.4 pp | Each quarter is listed in the row's details. |
| Operating margin | No value: not in the filings | No value: not in the filings | No value: not in the filings | No value: not in the filings |
| Net margin | 3.6% | −26.0 pp(worse for the company) | −1.4 pp | Each quarter is listed in the row's details. |
| Share count | 2.478B | −0.8%(better for the company) | −0.9% | Each quarter is listed in the row's details. |
How to read these figures
- Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
- 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
- Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
- 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
- n/m: not meaningful, such as a rate of change from a loss.
- Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.
Price
No closing prices are stored for this listing yet.
Facts
- Exchange
- New York Stock Exchange · USD
- Kind
- Common stock
- Security
- Common Stock